Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
The combination of IP and a first-in-class delivery platform gives Bexson an opportunity to bring their internal drug pipeline to market with significant differentiation and the ability to impact multiple therapeutic areas.
“...I believe Bexson’s formulation technology is a significant breakthrough that will allow small molecule therapies to be delivered subcutaneously in an efficient and efficacious manner...In addition, the application to a broad platform of therapies has the opportunity to greatly alleviate the burden of high costs while supporting patient preference”, commented Dr. Langer.
“I see this as the future of Ketamine treatment in psychiatry. A form of Ketamine that offers higher efficacy with ease of implementation would ultimately increase the number of psychiatrists that adopt the treatment. Patients would ultimately be better served by the provider that they already know…”
"Bexson’s automated approach to controlled subcutaneous delivery can bring the efficacy of highly established IV standards to psychiatric offices, but without the procedural burden that limits adoption.”
"I’ve watched the Bexson founders and team from the start of their mission, tracking their vision and strategy as they developed and expanded their formulation IP and delivery platform over the last few years. Bexson’s innovations create a new pathway for the safe and controlled administration of several parenteral medications, potentially transforming the care of debilitating medical and mental health conditions.”
“I followed Bexson closely after meeting Dr. Jeffrey Becker, Bexson Co-Founder and CSO. Dr. Becker is a true visionary founder, physician, and biochemist. He personally helped me hack my own health for dramatically positive results and I consider him an authoritative source on clinical pharmacology.“
